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In vivo human lower extremity saphenous vein
bypass grafts manifest flow mediated vasodilation
Christopher D. Owens, MD, MSc,a Nicole Wake, BS, RVT,b Michael S. Conte, MD,a
Marie Gerhard-Herman, MD,b and Joshua A. Beckman, MD,b San Francisco, Calif; and Boston, Mass
Objective: As in arteries, venous endothelium modulates vessel homeostasis and tone. The effect of an arterialized
environment on venous endothelial function remains poorly understood. In particular, regulation of saphenous vein graft
(SVG) blood flow and lumen caliber remains undefined. We hypothesized that mature SVGs would exhibit endothelium-
dependent, flow-mediated vasodilation (FMD).We further hypothesized that endothelium-derived nitric oxide (NO)was
an important mediator.
Methods: Patients with femoral to popliteal artery SVGs that hadmaintained primary patency and were at least 1 year from
surgery were enrolled. High-resolution, B-mode ultrasound scans were used to measure vein graft diameter before and 1
minute after reactive hyperemia (RH) to determine FMD. RHwas created through application of 220 mmHg to the calf
for 5 minutes with a sphygmomanometric cuff. After a 10-minute recovery period, nitroglycerin-mediated, endothelium-
independent vasodilation was measured 3 minutes after administration of nitroglycerin 0.4 mg sublingually. Brachial
artery FMD was determined by validated techniques. L-NGmonomethyl arginine (L-NMMA; 1 mg/kg infusion over 10
minutes) was used in a subset of patients (n  6) to competitively inhibit endothelial NO synthase.
Results:Nineteen subjects were enrolled. The median age of the SVGs was 34.6 (21.0-49.7) months. SVG flow-mediated,
endothelium-dependent vasodilation was measured at 5.28%  3.1% mean change in lumen diameter (range, 1.99%-
9.36%; P < .0001 for diameter change). Nitroglycerin-mediated vasodilation was 3.7%  1.0%, (range, 16%-10.04%;
P< .005). Intravenous administration of L-NMMA abolished SVG FMD (5.7 1.4% before L-NMMA vs 0.01 0.01%
during L-NMMA infusion; P  .0088) and attenuated brachial artery FMD (7.54%  1.0% vs 5.7  1.4; P  .05).
Conclusion: SVGs manifest flow-mediated, endothelium-dependent, and nitroglycerin-mediated endothelium-independent
vasodilation. Vein graft endothelium-dependent FMD is likely mediated by NO. Further investigation will be required to
determine the role of endothelial function in vein graft patency. (J Vasc Surg 2009;50:1063-70.)The adaptation of the great saphenous vein (GSV) to
the arterial environment in vivo has been described in
part.1-3 There are apparent temporally distinct patterns of
geometric remodeling, characterized by early lumen dilata-
tion followed later by wall thickening and stiffening of the
venous conduit. These changes are thought to be reactive
physiologic responses to the governing arterial hemody-
namic forces, shear stress, and radial wall stress. In particu-
lar, blood flow, and shear stress are directly correlated with
lumen dilation over the first month after implantation.
However, we have previously shown that shear stress alone
accounts for less than one-third of the biologic variability
seen in early lumen dilatation of saphenous vein graft
(SVG), implying that unaccounted variables are operative.3
In arteries, the changes in blood flow and shear forces
induce endothelium-dependent changes in vessel caliber. Pre-
vious in vivo studies of human coronary SVG used acetyl-
choline (Ach) as an agonist to study receptor-mediated,
From the Division of Vascular and Endovascular Surgery, University of
California San Francisco,a and the Department of Cardiology, Division of
Cardiovascular Medicine, Brigham and Women’s Hospital.b
Competition of interest: none.
Presented at the Western Vascular Society Meeting, Napa, Calif, September
15, 2008.
Reprint requests: ChristopherD.Owens,MD,MSc,University of California
San Francisco, 400 Parnassus Avenue, A-581, San Francisco, CA 94143-
0222 (e-mail: Christopher.Owens@ucsfmedctr.org).
0741-5214/$36.00
Copyright © 2009 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.06.022endothelium-dependent vasodilation. The role of the phys-
iologically relevant stimulus blood flow remains unex-
plored.4-6 Harvesting of the GSV and preparation for by-
pass injures the vein, denudes the endothelial cell surface,
and subjects it to ischemia and reperfusion.7,8 This damage
induces an inflammatory response within the vessel wall and
has been shown to decrease the amount and function of
endothelial nitric oxide synthase (eNOS) and endothelium-
derived nitric oxide (NO), hence impairing normal homeo-
static mechanisms of the vessel.9-12 This injury has been
implicated in early vein graft failure and thought to be permis-
sive for the formation of myointimal hyperplasia.12-14
Moreover, mature vein grafts may require endothelium-
dependent vessel homeostasis for maturation and survival.
Based on the observed changes in graft morphology after by-
pass, we hypothesized that mature human functioning SVGs
would manifest flow-mediated, endothelium-dependent va-
sodilatation and that NO would be the primary vasoactive
mediator.
METHODS
Subjects. Nineteen subjects with a continuously patent
femoral-to-popliteal arterial bypass with autogenous GSV,
performed for either claudication or critical limb ischemia,
were recruited for this study. All bypass grafts were at least
365 days old and none had undergone a revision to main-
tain patency. Bypass grafts were all tunneled superficially
and were in the nonreversed configuration. All subjects
underwent screening medical history and a vascular exam-
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ensure the absence of occult stenosis within the bypass
graft. All participants provided written informed consent.
The protocol was approved by the Human Research Com-
mittee of the Brigham and Women’s Hospital.
Vascular reactivity studies. Subjects were studied
in a quiet, temperature-controlled, dimly-lit room after
resting supine for a minimum of 5 minutes. Endothelium-
dependent and endothelium-independent vasodilation of
the SVG and endothelium-dependent vasodilatation of the
brachial artery were studied in the morning in the postab-
sorptive state fasting after the previous midnight. All vaso-
active medication, long-acting nitrates, tobacco, and caffeine
were withheld 24 hours before the study. High-resolution
B-mode ultrasonography scan of the brachial artery and
vein graft was performed using a GE Vivid 7 (GE Health-
care, Fairfield, Conn) ultrasound machine and a 7.5 MHz
linear array probe. The brachial artery was imaged longitu-
dinally, just proximal to the antecubital fossa, with the
transducer position adjusted to obtain optimal B-mode
images of the near and far walls of the intima. The video
output and electrocardiographic signal of the ultrasound
machine were connected to a computer equipped with a
data translation frame-grabber video card (Dataviz,Milton,
Conn). The R-wave on the electrocardiogram served as a
trigger to acquire frames at end-diastole. All postprocessing
imaging analysis was performed with the Brachial Analyzer
(Medical Imaging Applications, Iowa City, Iowa) by two
examiners in a blinded fashion. This software application
uses edge-detection and wall-tracking software which is
independent of investigator bias to capture 10 consecutive
end-diastolic images. The lumen diameter is reported as an
average of the 10 images.
Measurement of brachial artery flow mediated,
endothelium-dependent vasodilation. After baseline im-
age acquisition, a 2.5-inch wide sphygmomanometric cuff
was inflated to suprasystolic pressure (220 mm Hg) for 5
minutes. The duplex scan probe remained in position over
the brachial artery to ensure complete absence of blood
flow through the brachial artery during cuff inflation. On
cuff release, RH causes blood flow to increase through
the brachial artery subserving the forearm. Flow-induced
endothelium-dependent vasodilation of the brachial artery
was determined by acquiring images at 1 minute after cuff
deflation. The determination of endothelial function was
performed in accordance with published guidelines.15 The
inter- and intraobserver variability in our laboratory has
been previously described.16 In this experiment, the abso-
lute mean difference between two ultrasound readers
(C.D.O. and N.W.) for measuring vein graft diameter was
(mean  SD) 3  129 micrometers.
Measurement of vein graft endothelium-dependent
and endothelium-independent vasodilation. The vein
graft was imaged in a straight, valveless segment chosen
after the surveillance scan was performed. A 2.5-inch wide
sphygmomanometric cuff was placed slightly below the
tibial tuberosity and inflated to suprasystolic pressure for 5
minutes (Fig 1, a). The cuff was never placed directly overthe graft. Flow induced, endothelium-dependent vasodila-
tion of the vein graft was determined by acquiring images
at 1 minute after cuff deflation (Fig 1, b, c). Ten minutes
after cuff release, the vein graft was re-imaged to ensure
Fig 1. Schematic of lower extremity cuff-induced ischemia tech-
nique. a,The superficial femoral artery is occluded and a saphenous
vein bypass is shown. The cuff is placed distal to the distal anasto-
mosis and inflated to suprasystolic pressures. b, Doppler spectral
waveform of the vein graft demonstrating baseline, and (c) hyper-
emic flow patterns.return to basal conditions. Then, to determine endothelium-
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glycerin, sublingually. The vein graft was imaged 3 minutes
later. Nitroglycerin was not administered if the systolic
blood pressure was 100 mm Hg. Fifteen of the 19 sub-
jects received nitroglycerin.
Administration of L-NMMA. In the last 6 consecu-
tive patients, we tested the hypothesis that the mediator of
vein graft flow mediated dilation was NO. These patients
received intravenous administration of L-NGmonomethyl
arginine (L-NMMA) at a dose of 1 mg/kg infused over 10
minutes to competitively inhibit the production of NO.
During infusion, all patients were evaluated with noninva-
sive blood pressure monitoring and queried for adverse
reactions such as chest pain or shortness of breath every 2
minutes. Vein graft endothelium-dependent vasodilation
was assessed as described above. Ten minutes after cuff
release, the vein graft was re-imaged to ensure return to
baseline. Once baseline size was re-established, L-NMMA
infusion was initiated and vein graft vasodilation was as-
sessed again after 10 minutes. All patients remained in a
monitored environment until their blood pressure returned
to baseline.
Hemodynamic measurements. Volumetric flow, Q,
was calculated by integrating the area under the velocity
spectral waveform and dividing by time to arrive at a
time-averaged velocity. Mean flow was calculated by mul-
tiplying the time-averaged velocity by the mean area of the
lumen. The integral was calculated using the brachial
Doppler flow analysis package (Medical Imaging Applica-
tions).
Statistical methods. Based on a sample size of 19, the
power to detect3% change in vein graft diameter, assum-
ing a SD of 3% (a value typical for our laboratory), was 98%
using a two-sided, one sample t test.
Descriptive measures are reported as means  SD.
Experimental measures are reported as means  SD.
Experimental measures, including flow-mediated and
nitroglycerin-mediated vasodilation (NMD) for each sub-
ject group were compared using a paired t test. Linear
regressions were performed to determine correlation be-
tween continuous variables and Pearson’s correlation coef-
ficient reported in variables with normal distributions. Sta-
tistical significance was accepted at the 95% confidence level
(P  .05). All statistics were performed with STATA 10
(College Station, Tex).
RESULTS
Demographic characterizations. Nineteen subjects,
14 male (74%), were enrolled with a mean age of 64.7 
9.0 years. All subjects had a stable functioning femoral-to-
popliteal bypass graft with autogenous vein that had not
been revised. The mean time from surgery to enrollment
was 1196  785 days and no patient had a bypass for less
than 1 year. The indication for bypass was claudication in
13 patients, rest pain or ulceration in 5, and popliteal artery
aneurysm in 1. The prevalence of diabetes in this cohort was
11/19 (57.9%), 7/19 (36.8%) were active smokers, coro-nary artery disease 10/19 (52.6%), and hypertension 8/19
(42.1%), (Table I).
Vascular function studies
Brachial artery. Baseline brachial artery diameter was
3.51  0.64 mm and increased to 3.83  0.67 mm 60
seconds after deflation of the cuff for a flow-mediated
vasodilation of 9.21  4.6%, P  .0001 for the change
(Table II). Brachial artery volumetric flow increased from
207.64  96.95 at baseline to 1050.22  548.46 mL/
minute, P .0001 during RH. In this cohort, there was no
association with brachial artery FMD and cardiovascular
risk factors.
Vein graft. Baseline vein graft characteristics are pre-
sented in Table II. Baseline vein graft time-averaged, volu-
metric flow was 348.0  153.2 mL/minute and increased
to 1097 781.1mL/minute after cuff deflation represent-
ing a mean increase of 233%, P .0001 (Fig 2, a). This was
significantly less than the reactive hyperemic stimulus seen
in the brachial artery, 233 41% for the vein vs 430 40%
for the brachial artery, P  .0001. Baseline vein graft
diameter was 4.66  0.82 mm and increased to 4.89 
0.82 mm after cuff deflation, P  .0001 (Fig 2, b). Vein
graft flow-mediated, endothelium-dependent vasodilation
was 5.28%  3.1% (range, 1.99%-9.36%) for the entire
cohort (Fig 2, c) which was significantly less than brachial
artery FMD, P .009. There was a suggestion of an inverse
correlation between vein graft FMD and baseline vein graft
diameter, r -0.46 (95% CI -0.73, 0.04), P .067. There
was no observed association between vein graft vasodilata-
tion and tibial runoff, nor an association between vein graft
FMD and cardiovascular risk factors.
Flow-mediated vasodilation is, in part, determined by
the amount of the RH response to cuff occlusion. To
Table I. Study population demographics
Variable N (%)
Race (white) 16 (84.2%)
Gender (male) 14 (73.7%)
CAD 10 (52.6%)
Diabetes 11 (57.9%)
Hypertension 8 (42.1%)
Hyperlipidemia 10 (52.6%)
Meds
Aspirin 19 (100%)
Statin 13 (68.4%)
B-blocker 14 (73.7%)
Runoff score*
1 vessel 2 (11.8%)
2 vessel 7 (41.2%)
3 vessel 8 (47.1%)
Age of graft (days  SD) 1195.6  785.2
eGFR (mean  SD) 69.0  30.3
HgbA1c (mean  SD) 6.6  0.94
Total cholesterol (mean  SD) 155.5  62.1
CAD, Coronary artery disease; eGFR, estimated glomerular filtration rate;
HgbA1c, hemoglobin A1c.
*Runoff score calculated as number of patent vessels to the foot.examine the role of flow in each vascular bed, a vasoreac-
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FMD response to the flow stimulus by dividing percent
FMD by the percent change in volumetric flow during RH.
After normalization to the stimulus, there was no signifi-
cant difference in the VI of the vein grafts and the brachial
artery, 0.029  0.007 vs 0.039  0.007, P  .13. Al-
though there was no correlation between unadjusted vein
graft FMD and brachial artery FMD, after normalization
for flow there was a significant correlation between vein
graft vasoreactivity and that of the brachial artery, r 0.64
(95% CI 0.24-0.85), P  .004 (Fig 3).
Sublingual nitroglycerin (0.4 mg) was given to assess
vein graft endothelium-independent vasodilation (NMD).
All patients who had a systolic blood pressure greater than
100 mm Hg were eligible to receive nitroglycerin, n  16.
All vein grafts were re-imaged after 10 minutes to ensure a
return to baseline diameter. Nitroglycerin produced a non-
significant 13% increase in time-averaged, volumetric flow
through the SVGs and resulted in an increase in vein graft
diameter from 4.69  0.81 mm to 4.87  0.90 mm, P 
.015 (Table II and Fig 2, c). In this cohort, NMD was
3.68  1.0% (range, 0.16%-10.04%) (Fig 2, c).
Administration of L-NMMA. Six subjects received
L-NMMA. All patients experienced an increase in systolic
blood pressure upon administration, and the mean increase
in systemic blood pressure after administration was 17.8
mm Hg, P  .05. Despite the increase in blood pressure,
there was no change in the baseline size (P  .67 and P 
.50) or blood flow (P  .25 and P  .90) of the brachial
artery or SVGs, respectively.
Before L-NMMA, brachial artery flow-mediated vaso-
dilation was 7.54 1%. During L-NMMA administration,
brachial artery flow-mediated vasodilation decreased to
5.67 1.36, for a 25% reduction in flow-mediated vasodi-
lation (P  .05, compared to pre L-NMMA administra-
tion; Fig 4, a).
Before L-NMMA, SVG flow-mediated vasodilation
was 5.66  3.34. During L-NMMA administration, SVG
flow-mediated vasodilation decreased to -0.01 0.034, for
a 100% reduction in flow-mediated vasodilation (P 
.0088, compared to pre L-NMMA administration). There
were no adverse events during L-NMMA administration
(Fig 4, b).
Discussion. Several novel findings are noted in this
investigation. First, these experiments demonstrate that
Table II. Baseline and hyperemic vein graft and brachial a
Baseline diameter
(mm  SD)
RH
(m
Endothelium-dependent vasodilation
Vein graft 4.66  0.82 4.8
Brachial artery 3.51  0.64 3.8
Endothelium-independent vasodilation
Vein graft 4.69  0.81 4.8
RH, Reactive hyperemia.mature lower extremity human saphenous vein bypassgrafts have functioning endothelium and are capable of
undergoing flow mediated vasodilation, implying the pres-
ence of a physiologically functional endothelium. Further,
we showed that the primary mediator of vein graft FMD is
endothelium-derived NO demonstrated by the elimination
of vasodilatation during systemic infusion of the endothe-
lial nitric oxide synthase inhibitor, L-NMMA. Second, we
have also shown that these grafts manifest nitroglycerin-
mediated, endothelium-independent vasodilation, but to a
lesser extent than similar size arteries. This phenomenon
has also been observed in aortocoronary venous bypass
grafts when exposed to nitroglycerin or sodium nitroprus-
side, both exogenous NO donors.6,17 Third, we have
shown, we believe for the first time, that brachial artery
FMD in patients with established atherosclerosis is partially
mediated by NO. Previously, the role of NO in conduit
artery vasodilatation had been reported only in healthy
subjects.
We have also shown, we believe for the first time, that
there is an apparent correlation between FMD of the bra-
chial artery and that of mature functioning vein grafts.
Although previous work has demonstrated a relationship
between peripheral and coronary artery endothelium-
dependent vasodilation,16 a relationship between peripheral
artery and vein graft endothelial function has not been
described. This suggests that vein grafts, despite the lack of
mature lamellar subunits,7 may be capable of adapting over
time such that their endothelial and smooth muscle cell
function responds in a similar fashion to that of peripheral
conduit arteries. Whether or not brachial artery vasodila-
tory capacity may be used as a surrogate for the vein graft
endothelial function is an interesting question to be exam-
ined in further studies. Other investigators have normalized
FMD response either peak shear rate or area under the
postinflation shear rate curve with the latter having a higher
correlation.18 In both cases, the FMD response is, at least in
part, regulated by the amount of the stimulus (reactive
hyperemia) applied. The best method for relating these
variables remains under active investigation.
The RH flow stimulus was significantly less in the vein
graft than in the brachial artery in the arm which may, in
part, explain the absolute difference between vein graft and
brachial flow mediated dilatation. By placing the occlusion
cuff distal to the vein graft over the popliteal artery, the
morphometrics
meter
SD)
Delta diameter
(%  SD)
Baseline Q
(mL/min  SD)
RH Q
(mL/min  SD)
0.82 5.28  3.1% 348.0  153.2 1096.6  781.1
0.67 9.21  4.6% 207.64  96.95 1050.22  548.46
0.90 3.68  4.4% 362.78  90.76 410.03  155.73rtery
dia
m 
9 
3 
7 blood flow was not restricted in the leg to the same degree
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we did not place the cuff directly over the vein graft.
Vein graft vascular tone modulation. There is rela-
tively little known about the biomechanical changes of the
endothelium of SVGs during maturation in the arterial
circulation. Both animal and human studies have demon-
strated that the endothelium-dependent vasodilator re-
sponse to Ach is substantially weaker in preimplantation
veins than in arteries.19 However, animal studies have also
demonstrated that there exists a biochemical adaptation of
venous endothelium to the arterial environment including
an augmented vasodilator response to cholinergic stimula-
tion and an augmented vasodilator prostaglandin produc-
tion.20,21 This implies a plasticity to the endothelium that
may be important in successful vein graft maturation. For
example, chronic exposure to higher pressure and pulsatile
flow increases endothelium-derived relaxing factors in
arteries.22,23
Ex vivo human studies have demonstrated varied endo-
thelial and smooth muscle cell reactivity in preimplantation
veins and vein grafts, a finding that may reflect the timing in
which the experiment was conducted, and the stimulant
used.17,24 Luscher et al17 noted that Ach-stimulated,
endothelium-dependent relaxation was significantly less in
SVG rings compared to internal mammary artery rings
harvested at the time of surgery but before exposure to the
arterial environment. In these experiments, the saphenous
veins were capable of endothelium-independent relaxation
suggesting preserved smooth muscle cell function. Davies
Fig 2. a, Volumetric flow through human saphenous vein grafts
(SVG) under basal and hyperemic conditions and pre and post
0.4 mg sublingual nitroglycerin. b, Endothelium-dependent and
-independent vasodilatation in human saphenous vein bypass
grafts. Baseline reflects baseline vein graft diameter. c, Flowmediated
dilatation (FMD) and nitroglycerin mediated dilatation (NMD) in
r=.64, P=.004
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Fig 3. Regression analysis demonstrating a significant positive
correlation between brachial artery and vein graft flow mediated
dilation once normalized to reactive hyperemia (RH) flow stimu-
lus, r  0.64, P  .004. FMD, Flow mediated dilatation.human SVGs. RH, Reactive hyperemia;NTG, nitroglycerin.
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tive cardiac surgery, precontracted SVG rings failed to relax
in response to Ach compared with ungrafted saphenous
veins. The abnormality in cholinergic-mediated eNOS ac-
tivationmay result from the vein graft intimal hyperplasia or
atheromata severe enough to require re-bypass, similar
to the response in atherosclerotic coronary arteries.26 Ku
et al,24 has demonstrated that cardiac vein grafts retain
their ability to relax ex vivo to Ach and calcium ionophore
for as many as 12 years, suggesting preserved cholinergic-
mediated endothelium-dependent relaxation.
Common to each of the above-mentioned studies was
the use of Ach as a stimulus to test endothelial function in
grafts. However, the observation noted by some investiga-
tors of the decreased ability of SVGs rings to relax in
response to Ach,27,28 must be tempered by the observation
that others report that venous rings relax to a greater extent
to A23187 (calcium ionophore), a receptor-independent
(but endothelium-dependent) mechanism of vasorelax-
ation.27,29,30 The significance of this discrepancy may be
related to muscarinic receptor density differences in veins
or vein grafts than in arteries rather than simply NO
Fig 4. The contribution of nitric oxide (NO) to brachial artery
and vein graft flow mediated dilatation (FMD) was examined by
systemically infusing L-NGmonomethyl arginine (L-NMMA). Al-
though NO contributes to brachial artery FMD in atherosclerotic
patients, P  .05, (a) NO is likely the primary mediator of vein
graft FMD, P  .0088 (b).bioavailability.29,31A novel feature of the present study distinct from the
above-mentioned studies is the reliance on the more phys-
iologically relevant stimulus, hyperemic flow, in contrast to
Ach. Flow may be an important regulator of vein graft
homeostasis as evidenced by the greater rate of bypass graft
failure in grafts with lower flows.32 Whether or not endo-
thelial function as measured here relates to veinmaturation,
or clinical events such as graft patency, is an area of ongoing
investigation.
The relative importance of NO in vein graft vasodilator
modulation can be inferred from several observations. First,
NMD was similar to FMD suggesting that the arterial
environment may maintain the vein graft near maximal
vasodilation. We surmise the reduced nitroglycerin re-
sponse occurred because of a more persistent vasodilatory
state or a relative paucity of vascular smooth muscle com-
pared to arteries. In coronary artery SVGs, vasodilatation is
greater to nitroglycerin infusion.33 In contrast to leg bypass
SVGs, nitroglycerin also increases flow through coronary
arteries facilitating a second mechanism of vasodilatation.
The second important observation is the relative reduction
in FMD with L-NMMA. FMD was abolished in SVG but
only halved in the brachial arteries of our subjects, similar to
previous work.34 Our subjects were all treated with aspirin
as part of their atherosclerosis management, suggesting
that prostaglandins did not importantly participate in these
findings. We surmise that SVGs rely to a greater extent on
NO whereas conduit arteries employ subsidiary vasodila-
tors, such as endothelium-derived hyperpolarizing factor to
maintain some vasodilatory capacity.
The implication in the ability to detect flow-mediated
vasodilation in mature, patent, human lower extremity
SVGs is that they have a functioning endothelial layer
capable of producing NO. Nitric oxide confers the vessel
with thrombo-resistance by inhibiting platelet aggregation,
thrombus formation, leukocyte adherence, and vascular
smooth-muscle proliferation. Thus, a well-functioning en-
dothelial cell layer would be critical for maintaining bypass
graft patency and may, in part, explain the superior patency
rates of SVGs over prosthetic conduits. The initial injury to
SVG endothelial function during harvesting has never been
characterized in humans. The ability to quantify endothe-
lial injury and to ascertain functional endothelial recovery
may allow targeted and timely therapy to prevent myointi-
mal hyperplasia. The finding that the endothelial function
of the vein graft is as robust, for a given stimulus, as that of
the brachial artery suggests an ontogeny of the maturing
vein as it adapts in its role as an arterial substitute.
Limitations. This was a select cohort of patients cho-
sen to minimize variability and maximize our ability to
detect a response. Therefore, we chose patients who had a
mature functioning conduit, free of hemodynamically sig-
nificant stenosis for over 1 year. As such, these conduits
were arterialized at baseline and, therefore, represented
real-life functional bypass physiology.
We elected not to use a norepinephrine vasoconstrictor
control arm to equivalently raise the systolic blood pressure
to a similar extent as the L-NMMA. We justified this
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brachial artery and vein grafts at baseline during L-NMMA
infusion. Nevertheless, it is possible that the acute increase
in wall stress induced may have increased local production
of reactive oxygen species (ROS), thus limiting the bioavail-
ability of NO. This has been described in arteries but, to our
knowledge, has never been described in the vein bypass.
The kinetics of vein graft FMD response, in terms of
duration of cuff inflation35 and time to peak FMD36 were
not explored in this study. Previous studies in arterial
conduit arteries, including the superficial femoral artery,
indicate that FMD response to longer cuff inflation times
(5 minutes) are not purely mediated by NO.37 In addi-
tion, other reports suggest that measurement of FMD
60-80 seconds after a 5-minute period of cuff-induced
ischemia,15 may underestimate the maximal response.36,38
Now that vein graft FMD response has been established,
kinetic studies represent an interesting line of investigation
to determine whether the pattern varies from conduit arteries.
Finally, the number of subjects does not permit the
determination of statistical association with known modifi-
ers of FMD, such as cardiovascular risk. In addition, given
the multiple comparisons performed in this study, there
exists the possibility of type 1 (false positive) error. How-
ever, this does not detract from the experimentally derived
observation that vein grafts manifest FMD.
Summary. We have shown that mature, human SVGs,
free of hemodynamically-significant stenosis, manifest
endothelium-dependent and endothelium-independent vaso-
dilatation. Furthermore, by abolishing flow mediated vaso-
dilatation with the competitive inhibitor of L-arginine,
L-NMMA, these data suggest that the principal mediator
responsible for vein graft flow mediated dilatation is NO.
We have also shown, we believe, for the first time that
mature lower extremity bypass grafts are capable of re-
sponding to a flow stimulus as robustly as does the brachial
artery. These observations build on the conceptual frame-
work that the lower extremity SVG undergoes considerable
mechanical and biochemical adaptation in its role as a small
artery substitute and may provide a window into predicting
vein graft survival in patients.
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